Regeneron Pharmaceuticals, Inc. REGN
Transcripts49
Date range2013-05-03 – 2025-04-29
Calls charted49
Sentiment timeline
Net Loughran-McDonald sentiment per call (×1000), earliest → latest.
CEO vs CFO
Average sentiment of each executive's remarks per call. Divergence is a signal.
Prepared remarks vs Q&A
Scripted tone vs unscripted answers. The gap is information.
Prepared remarksQ&A responses
Tone vs forward expectations
Management tone next to Wall Street's forward-looking numbers (glopardo): the 12-month forward EPS estimate and the forward P/E per call.
Forward EPS estimate
Forward P/E
Divergence watch ⚑
Quarters where tone and the forward EPS estimate moved opposite ways.
- 2014 Q3
tone ↓ -4.3
fwd EPS ↑ +0.82
Tone cooled even as the forward EPS estimate rose.
- 2016 Q2
tone ↓ -2.4
fwd EPS ↑ +0.49
Tone cooled even as the forward EPS estimate rose.
- 2018 Q2
tone ↓ -2.6
fwd EPS ↑ +0.86
Tone cooled even as the forward EPS estimate rose.
- 2019 Q4
tone ↓ -4.8
fwd EPS ↑ +1.35
Tone cooled even as the forward EPS estimate rose.
- 2020 Q4
tone ↓ -2.6
fwd EPS ↑ +4.15
Tone cooled even as the forward EPS estimate rose.
- 2021 Q3
tone ↓ -2.1
fwd EPS ↑ +4.78
Tone cooled even as the forward EPS estimate rose.
- 2023 Q4
tone ↓ -2.6
fwd EPS ↑ +0.92
Tone cooled even as the forward EPS estimate rose.
- 2024 Q1
tone ↓ -8.6
fwd EPS ↑ +1.48
Tone cooled even as the forward EPS estimate rose.
Recent transcripts
| Call | Date | Sentiment ×1000 | Fwd EPS | Fwd P/E | |
|---|
| 2025 Q1 | 2025-04-29 | +1.0 | — | — | View → |
| 2024 Q4 | 2025-02-04 | +8.5 | — | — | View → |
| 2024 Q3 | 2024-10-31 | +6.0 | $47.98 | 23.7 | View → |
| 2024 Q2 | 2024-08-01 | +6.8 | $46.04 | 22.6 | View → |
| 2024 Q1 | 2024-05-02 | -3.1 | $45.35 | 21.3 | View → |
| 2023 Q4 | 2024-02-02 | +5.5 | $43.87 | 20.0 | View → |
| 2023 Q3 | 2023-11-02 | +8.1 | $42.95 | 19.2 | View → |
| 2023 Q2 | 2023-08-03 | +3.9 | $42.47 | 18.2 | View → |